343 related articles for article (PubMed ID: 36754548)
21. Efficacy of tofacitinib in reducing pain in patients with rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis.
Ogdie A; de Vlam K; McInnes IB; Mease PJ; Baer P; Lukic T; Gruben D; Kwok K; Wang C; Hsu MA; Maniccia A
RMD Open; 2020 Feb; 6(1):. PubMed ID: 32396519
[TBL] [Abstract][Full Text] [Related]
22. Predicting adherence to therapy in rheumatoid arthritis, psoriatic arthritis or ankylosing spondylitis: a large cross-sectional study.
Smolen JS; Gladman D; McNeil HP; Mease PJ; Sieper J; Hojnik M; Nurwakagari P; Weinman J
RMD Open; 2019; 5(1):e000585. PubMed ID: 30713716
[TBL] [Abstract][Full Text] [Related]
23. Upadacitinib Versus Placebo or Adalimumab in Patients With Rheumatoid Arthritis and an Inadequate Response to Methotrexate: Results of a Phase III, Double-Blind, Randomized Controlled Trial.
Fleischmann R; Pangan AL; Song IH; Mysler E; Bessette L; Peterfy C; Durez P; Ostor AJ; Li Y; Zhou Y; Othman AA; Genovese MC
Arthritis Rheumatol; 2019 Nov; 71(11):1788-1800. PubMed ID: 31287230
[TBL] [Abstract][Full Text] [Related]
24. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
[TBL] [Abstract][Full Text] [Related]
25. Opioid use surrounding diagnosis and follow-up in patients with ankylosing spondylitis, psoriatic arthritis, and rheumatoid arthritis: Results from US claims databases.
Sheahan A; Anjohrin S; Suruki R; Stark JL; Sloan VS
Clin Rheumatol; 2024 Jun; 43(6):1897-1907. PubMed ID: 38658403
[TBL] [Abstract][Full Text] [Related]
26. Tuberculosis among patients treated with TNF inhibitors for rheumatoid arthritis, ankylosing spondylitis and psoriatic arthritis in Slovenia: a cohort study.
Rotar Z; Svetina P; Tomsic M; Hočevar A; Prapotnik S
BMJ Open; 2020 Feb; 10(2):e034356. PubMed ID: 32029494
[TBL] [Abstract][Full Text] [Related]
27. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
[TBL] [Abstract][Full Text] [Related]
28. Upadacitinib in Rheumatoid Arthritis: A Benefit-Risk Assessment Across a Phase III Program.
Conaghan PG; Mysler E; Tanaka Y; Da Silva-Tillmann B; Shaw T; Liu J; Ferguson R; Enejosa JV; Cohen S; Nash P; Rigby W; Burmester G
Drug Saf; 2021 May; 44(5):515-530. PubMed ID: 33527177
[TBL] [Abstract][Full Text] [Related]
29. Observational study of switching anti-TNF agents in ankylosing spondylitis and psoriatic arthritis versus rheumatoid arthritis.
Haberhauer G; Strehblow C; Fasching P
Wien Med Wochenschr; 2010 May; 160(9-10):220-4. PubMed ID: 20632149
[TBL] [Abstract][Full Text] [Related]
30. Safety of upadacitinib in moderate-to-severe atopic dermatitis: An integrated analysis of phase 3 studies.
Guttman-Yassky E; Thyssen JP; Silverberg JI; Papp KA; Paller AS; Weidinger S; Chih-Ho Hong H; Hendrickson B; Dilley D; Tenorio AR; Ladizinski B; Chu AD; Liu J; Irvine AD
J Allergy Clin Immunol; 2023 Jan; 151(1):172-181. PubMed ID: 36195170
[TBL] [Abstract][Full Text] [Related]
31. Patient-reported outcomes with golimumab in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: non-interventional study GO-NICE in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
Rheumatol Int; 2019 Jan; 39(1):131-140. PubMed ID: 30415451
[TBL] [Abstract][Full Text] [Related]
32. Effectiveness and safety of golimumab in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis under real-life clinical conditions: non-interventional GO-NICE study in Germany.
Krüger K; Burmester GR; Wassenberg S; Bohl-Bühler M; Thomas MH
BMJ Open; 2018 Jun; 8(6):e021082. PubMed ID: 29903793
[TBL] [Abstract][Full Text] [Related]
33. Treatment persistence among patients with rheumatoid disease (RA, AS, PsA) treated with subcutaneous biologics in Germany.
Lyu R; Govoni M; Ding Q; Black CM; Kachroo S; Fan T; Ogbonnaya A; Donga P; Hill J; Makin C
Rheumatol Int; 2016 Jan; 36(1):143-53. PubMed ID: 26314368
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial.
van der Heijde D; Song IH; Pangan AL; Deodhar A; van den Bosch F; Maksymowych WP; Kim TH; Kishimoto M; Everding A; Sui Y; Wang X; Chu AD; Sieper J
Lancet; 2019 Dec; 394(10214):2108-2117. PubMed ID: 31732180
[TBL] [Abstract][Full Text] [Related]
35. Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry.
Manara M; Caporali R; Favalli EG; Grosso V; Atzeni F; Sarzi Puttini P; Gorla R; Bazzani C; Fusaro E; Pellerito R; Rocchetta PA; Sinigaglia L
Clin Exp Rheumatol; 2017; 35(5):804-809. PubMed ID: 28770712
[TBL] [Abstract][Full Text] [Related]
36. Upadacitinib in patients with psoriatic arthritis and an inadequate response to non-biological therapy: 56-week data from the phase 3 SELECT-PsA 1 study.
McInnes IB; Kato K; Magrey M; Merola JF; Kishimoto M; Pacheco-Tena C; Haaland D; Chen L; Duan Y; Zueger P; Liu J; Lippe R; Pangan AL; Behrens F
RMD Open; 2021 Oct; 7(3):. PubMed ID: 34663636
[TBL] [Abstract][Full Text] [Related]
37. Routine Assessment of Patient Index Data 3 (RAPID3) in Patients with Rheumatoid Arthritis Treated with Long-Term Upadacitinib Therapy in Five Randomized Controlled Trials.
Bergman M; Buch MH; Tanaka Y; Citera G; Bahlas S; Wong E; Song Y; Zueger P; Ali M; Strand V
Rheumatol Ther; 2022 Dec; 9(6):1517-1529. PubMed ID: 36125701
[TBL] [Abstract][Full Text] [Related]
38. Long-term golimumab persistence: Five-year treatment retention data pooled from pivotal Phase III clinical trials in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis.
Weinstein CLJ; Meehan AG; Lin J; Briscoe SD; Govoni M
Clin Rheumatol; 2023 Dec; 42(12):3397-3405. PubMed ID: 37751000
[TBL] [Abstract][Full Text] [Related]
39. Safety and effectiveness of intravenous CT-P13 in inflammatory arthritis: post-marketing surveillance study in Thailand.
Mahakkanukrauh A; Chaiamnuay S; Koolvisoot A; Kitamnuayphong T; Manavathongchai S; Osiri M; Louthrenoo W; Uea-Areewongsa P; Ahn K; Jung N; Kim M; Lee S; Kim H; Kim S
Immunotherapy; 2023 Oct; 15(14):1143-1155. PubMed ID: 37589164
[TBL] [Abstract][Full Text] [Related]
40. Safety and efficacy of upadacitinib in patients with active rheumatoid arthritis refractory to biologic disease-modifying anti-rheumatic drugs (SELECT-BEYOND): a double-blind, randomised controlled phase 3 trial.
Genovese MC; Fleischmann R; Combe B; Hall S; Rubbert-Roth A; Zhang Y; Zhou Y; Mohamed MF; Meerwein S; Pangan AL
Lancet; 2018 Jun; 391(10139):2513-2524. PubMed ID: 29908670
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]